Ovid Therapeutics (OVID) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.10

Estimate

-$0.08

Surprise

-18.4%

Score today

5.8/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Ovid Therapeutics (OVID) reported a wider loss than forecast — adjusted EPS of -$0.10 against the -$0.08 estimate (a 18.4% shortfall).

• Ovid Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates — fiscal.ai, 2026-11-10
• Ovid Therapeutics Q3 EPS $(0.10) Misses $(0.09) Estimate — benzinga, 2026-11-10
• Ovid Therapeutics Reports Positive Early-Stage Trial Results for OV329 — fiscal.ai, 2026-11-09

TrendMatrix currently rates OVID Sell at 5.8/10; no pre/post engine snapshot brackets this report.

1 of the last 4 quarters beat the estimate; this quarter's -18.4% surprise compares with a +43.2% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$2.80

Price target

$5.57

Stop

$2.60

Upside to target

+98.9%

Reward-to-risk

6.6:1

Model outputs from TrendMatrix’s engine as of 2026-11-11 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$546.8M

P/E (fwd)

-7.3

52-week range

$1.18–$3.10

Off 52-week high

9.8%

RSI (14)

60

Volume vs avg

0.94×

Score today

5.8/10